Impacto presupuestario del tratamiento antirretroviral. Reflexión desde las guías de GESIDA.

Grupo de trabajo de la Cohorte VACH, Asociación Médica AM-VACH, Huelva, España.

Gac Sanit. 2012;26(6):541–546

Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naïve HIV-Infected Patients: GESIDA-5808 Study

Pérez-Molina JA, Mora Rillo M, Suárez-Lozano I, Casado-Osorio JL, Teira Cobo R, Rivas González P, Pedrol Clotet E, Hernando-Jerez A, Domingo P, Barquilla Díaz E, Esteban H, González-García J, For The Gesida 5808 Study Group.

HIV Clin Trials. 2012 May 1;13(3):131-141.

Calendar time trends in the incidence and prevalence of triple-class viroligic failure in antiretroviral drug experienced people with HIV in Europe

F Nakagawa for the PLATO II group for COHERE in EuroCoord. J

Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

The Pursuing Later Treatment Option II (PLATO II) project team* for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group.

Lancet Infect Dis 2012;12: 119–27

CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE

The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord (2012).

PLoS Med. 2012 Mar;9(3):e1001194.